(UroToday.com) The 2025 AUA annual meeting featured the IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder cancer, moderated by Dr. Patrick Hensley, with a debate ...

Sam Chang interviews Alice Yu about three practice-changing areas in urothelial carcinoma. Dr. Yu first discusses the NIAGARA trial, which demonstrated improved pathologic complete response, ...

Zachary Klaassen speaks with Pedro Barata about chemohormonal therapy and treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Barata traces the evolution from 2015 when ...

Optimal patient selection on the basis of prostate size, presence of a median lobe, and patient preferences is key to success for various minimally invasive surgical treatments for benign prostatic ...

This review synthesizes literature on how commonly prescribed medications-antihypertensives, statins, antidepressants, levothyroxine, proton pump inhibitors, phosphodiesterase type 5 inhibitors, and ...

Ashish Kamat interviews Patrick Soon-Shiong about expanding ANKTIVA® (NAI) indications to include papillary-only BCG-unresponsive bladder cancer. Dr. Soon-Shiong highlights three-year data showing 82% ...

Eric Kim interviews Aaron Berger about treatment approaches for high-risk prostate cancer and biochemical recurrence. Dr. Berger explains his balanced approach to treatment selection between surgery ...

Benign prostatic hyperplasia (BPH) is one of the most frequently diagnosed benign disorders that cause dysuria in middle-aged and elderly men. Some patients with BPH have relatively small prostates ...

We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized ...

Treating prostate cancer with radiation therapy in patients with a history of prior pelvic radiation may be limited by rectal dose constraints and the risk of rectal toxicity. Rectal spacers have been ...

Metastatic hormone-sensitive prostate cancer (mHSPCa) presents de novo or represents significant disease progression and requires systemic treatment. However, progression to castration resistance is ...

(UroToday.com) Today at the Engineering and Urology Society (EUS) Poster Session, Dr. Dan Stoianovici presented early clinical experience with ProBot, a newly developed robotic system designed to ...